Common use of Unsecured Junior Indebtedness Clause in Contracts

Unsecured Junior Indebtedness. subject to compliance with the Required Debt Terms; provided that immediately after giving effect to each such incurrence and the application of the proceeds therefrom, on a Pro Forma Basis (but without giving effect to any amounts incurred in connection herewith under the Fixed Incremental Amount) as of the Applicable Date of Determination and for the applicable Test Period, if such Test Period ends (i) on or prior to June 30, 2020, the LQA Recurring Revenue Leverage Ratio does not exceed 1.85 to 1.00, or (ii) after June 30, 2020, the Total Leverage Ratio does not exceed 5.25 to 1.00; provided further that the aggregate principal amount of Indebtedness incurred pursuant to this clause (t) by Restricted Subsidiaries that are not Credit Parties (taken together with any Indebtedness of Restricted Subsidiaries that are not Credit Parties pursuant to Section 6.01(u)) shall not exceed the greater of $3,750,000 and 20% of Consolidated EBITDA for the most recently ended Test Period at any time outstanding;

Unsecured Junior Indebtedness. subject to compliance with the Required Debt Terms; provided that immediately after giving effect to each such incurrence and the application of the proceeds therefrom, on a Pro Forma Basis (but without giving effect to any amounts incurred in connection herewith under the Fixed Incremental Amount) as of the Applicable Date of Determination and for the applicable Test Period, if such Test Period ends (i) on or prior to June 30, 2020, the LQA Recurring Revenue Leverage Ratio does not exceed 1.85 to 1.00, or (ii) after June 30, 2020, the Total Leverage Ratio does not exceed 5.25 to 1.00; provided further that the aggregate principal amount of Indebtedness incurred pursuant to this clause (t) by Restricted Subsidiaries that are not Credit Parties (taken together with any Indebtedness of Restricted Subsidiaries that are not Credit Parties pursuant to Section 6.01(u)) shall not exceed the greater of $3,750,000 3,750,0005,437,500 and 20% of Consolidated EBITDA for the most recently ended Test Period at any time outstanding;